The impact of diabetes or elevated fasting blood glucose on cardiovascular prognosis in patients with stable angina pectoris

Diabetic Medicine

Volumn 22, Issue 10, 2005, Pages 1326-1333

  Held, Claes ^a   Bjorkander I ^b   Forslund, L ^c   Rehnqvist, N ^d   Hjemdahl, P ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b DANDERYD HOSPITAL   (Sweden)

^c MEDICAL PRODUCTS AGENCY   (Sweden)

^d Swedish Council on Technology Assessment in Health Care   (Sweden)

Author keywords

Blood glucose; Cardiovascular disease; Diabetes; Prognosis; Stable angina pectoris

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; METOPROLOL; TRIACYLGLYCEROL; VERAPAMIL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; FEMALE; GENDER; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HIGH RISK POPULATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRACTICE GUIDELINE; PREDICTION; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDY; RISK FACTOR; STABLE ANGINA PECTORIS; TRIACYLGLYCEROL BLOOD LEVEL; VENOUS BLOOD;

ANGINA PECTORIS; ANTI-ARRHYTHMIA AGENTS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETIC ANGIOPATHIES; FASTING; FEMALE; HUMANS; MALE; METOPROLOL; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; VERAPAMIL;

EID: 25844443730     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2005.01643.x     Document Type: Article

References (37)

1. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham study. J Am Med Assoc 1979; 241: 2035-2038.
2. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-444.
3. Barrett-Connor E, Cohn BA, Wingard DL, Edelstein SL. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study. J Am Med Assoc 1991; 265: 627-631.
4. Manson JE, Coldlitz GA, Stampfer MJ, Willett WC, Krolewsk AS, Rosner B et al. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 1991; 151: 1141-1147.
5. Butler R, MacDonald TM, Struthers AD, Morris AD. The clinical implications of diabetic heart disease. Eur Heart J 1998; 19: 1617-1627.
6. Barbash GI, White HD, Modan M, Van de Werf F. Significance of diabetes mellitus in patients with acute myocardial infarction receiving thrombolytic therapy. J Am Coll Cardiol 1993; 22: 707-713.
7. Malmberg K, Rydén L. Myocardial infarctions in patients with diabetes mellitus. Eur Heart J 1988; 9: 259-264.
8. Ulvenstam G, Åberg A, Bergstrand R, Johansson S, Pennert K, Vedin A et al. Long-term prognosis after myocardial infarction in men with diabetes. Diabetes 1985; 34: 787-792.
9. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
10. Strandberg L-E, Ericsson C-G, O'Konor M-L, Bergstrand L, Lundin P, Rehnqvist N et al. Diabetes melitus is a strong negative prognostic factor in patients with myocardial infarction treated with thrombolytic therapy. J Int Med 2000; 248: 119-125.
11. Malmberg K, Yusuf S, Gerstein H, Brown J, Zhao F, Hunt D et al. for the OASIS Registry Investigators. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction. Circulation 2000; 102: 1014-1019.
12. Rosengren A, Wilhelmsen L, Hagman A, Wedel H. Natural history of myocardial infarction and angina pectoris in a general population sample of middle-aged men: a 16-year follow-up of the Primary Prevention Study, Göteborg, Sweden. J Int Med 1998; 244: 495-505.
13. American Diabetes Association. Report of the expert committees on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 1183-1197.
14. The DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999; 354: 617-621.
15. Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 2000; 355: 773-778.
16. Tenenbaum A, Motro M, Fisman E, Boyko V, Mandelzweig L, Reicher-Reiss H et al. Clinical impact of borderline and undiagnosed diabetes mellitus in patients with coronary artery disease. Am J Cardiol 2000; 86: 1363-1366.
17. Rehnqvist N, Hjemdahl P, Billing E, Björkander I, Eriksson SV, Forslund L et al. Effects of metoprolol versus verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS). Eur Heart J 1996; 17: 76-81 (erratum, p. 483).
18. Held C, Hjemdahl P, Rehnqvist N, Wallén NH, Forslund L, Björkander I et al. Hemostatic markers, inflammatory parameters and lipids in male and female patients in the Angina Prognosis Study in Stockholm (APSIS). A comparison with healthy controls. J Int Med 1997; 241: 59-69.
19. Forslund L, Hjemdahl P, Held C, Björkander I, Eriksson SV, Rehnqvist N. Ischaemia during exercise and ambulatory monitoring in patients with stable angina pectoris and healthy controls; gender differences and relationships to catecholamines. Eur Heart J 1998; 19: 578-587.
20. Norhammar A, Tenerz Å, Nilsson G, Hamsten A, Efendic S, Rydén L et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002; 359: 2140-2144.
21. Norhammar A, Rydén L, Malmberg K. Admission plasma glucose. Independent risk factor for long-term prognosis after myocardial infarction even in non-diabetic patients. Diabetes Care 1999; 22: 1827-1833.
22. Coutinho M, Gerstein H, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. Diabetes Care 1999; 22: 233-240.
23. Dargie HJ, Ford I, Fox KM, on behalf of the TIBET Study Group. Total Ischaemic Burden European Trial (TIBET): Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. Eur Heart J 1996; 17: 104-112.
24. Juul-Möller S, Edvardsson, N, Jahnmatz, B, Rosén, A, Sörensen, S, Ömblus, R, for the Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. Lancet 1992; 340: 1421-1425.
25. Davi G, Catalano I, Averna M, Notabartolo A, Strano A, Ciabattoni G, Patrono C. Thromboxane biosynthesis and platelet function in type II diabetes. N Engl J Med 1990; 322: 1769-1774.
26. Schneider DJ, Nordt TK, Sobel BE. Attenuated fibrinolysis and accelerated atherogenesis in type 2 diabetic patients. Diabetes 1993; 42: 1-7.
27. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels, a possible link between insulin resistance and atherothrombosis. Diabetologia 1991; 34: 457-462.
28. Williams SB, Goldfine AB, Timimi FT, Ting HH, Roddy M-A, Simonson DC et al. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 1998; 97: 1695-1701.
29. Laakso M, Lehto S, Penttilä I, Pyörälä K. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation 1993; 88: 1421-1430.
30. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic complications. Diabetes Care 1996; 19: 257-267.
31. Barzilay J, Spiekerman C, Kuller L, Burke G, Bittner V, Gottdiener J et al. Prevalence of clinical and isolated subclinical cardiovascular disease in older adults with glucose disorders. Diabetes Care 2001; 24: 1233-1239.
32. United Kingdom Prospective Diabetes Study. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
33. Hjemdahl P, Eriksson SV, Held C, Rehnqvist N. Prognosis of patients with stable angina pectoris on antianginal drug therapy. Am J Cardiol 1996; 77: 6D-15D.
34. Held C, Hjemdahl P, Rehnqvist N, Björkander I, Forslund L, Berglund L et al. Cardiovascular prognosis in relation to apolipoproteins and other lipid parameters in patients treated with verapamil or metoprolol. Atherosclerosis 1997; 135: 109-118.
35. The Swedish Council on Technology Assessment in Health Care (SBU). Moderately elevated blood pressure. Report. J Intern Med 1995; 238 (Suppl. 737): 1-225.
36. Lithell H. Metabolic aspects of the treatment of hypertension. J Hypertens 1995; 13: S77-S80.
37. β-Blocker Pooling Project Research Group. The β-blocker Pooling Project (BBPP): subgroup findings from randomized trials in post infarction patients. Eur Heart J 1988; 9: 8-16.